Ab­b­Vie and Roche tout a pos­i­tive PhI­II com­bo study of Ven­clex­ta, Rit­ux­an in CLL — ahead of FDA pitch

Ab­b­Vie and Roche are get­ting a boost out of the news that their com­bi­na­tion of Ven­clex­ta and Rit­ux­an met their pri­ma­ry end­point on pro­gres­sion-free sur­vival, beat­ing out a com­bi­na­tion of chemother­a­py and Rit­ux­an for treat­ment-re­sis­tant cas­es of chron­ic lym­pho­cyt­ic leukemia.

Ab­b­Vie says they’ll be hus­tling along the da­ta — none of which was on dis­play to­day — to reg­u­la­tors af­ter pick­ing up a break­through drug des­ig­na­tion on the com­bo for CLL, which has at­tract­ed a num­ber of drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER